Illumina/TruSeq Dual Index Sequencing Primer Box, Paired-End/PE-121-1003/1 Ea
Illumina 測序試劑盒 PE-121-1003

產品編號： PE-121-1003
美  元  價： $95.00
品       牌： Illumina
產       地： 美國
公       司： Illumina, Inc.
產品分類： 分子類>二代測序>簇生成和測序試劑
公司分類： Cluster Generation & Sequencing Reagents

Illumina公司創立于1998年4月，是遺傳變異和生物學功能分析領域的優秀的產品、技術和服務供應商。通過幫助客戶加快實現生物信息的采集、分析和應用，來改善人類健康。

Product Highlights:

The primers provided in the TruSeq Dual Index Sequencing Primer Box are required for sequencing the following libraries on the HiSeq 2500, HiSeq 2000, HiSeq 1500, HiSeq 1000 Systems; the HiScanSQ System using TruSeq SBS Kit v3; or the Genome Analyzer System.

The single-read kit should be used with a single-read flow cell, and the paired-end kit with a paired-end flow cell.

• Any Nextera library except Nextera Mate Pair
• Any library constructed with a Nextera or Nextera XT Index Kit
• Any TruSeq HT library when performing a dual-index run on a single-read flow cell
• A TruSeq Synthetic Long-Read DNA library
• Any TruSight library except TruSight RNA Pan-Cancer 
• A TruSeq Rapid Exome library
• A TruSeq Custom Amplicon library (v1.5 and Low Input) 
• A TruSeq Amplicon Cancer Panel library
• A VeriSeq PGS library

Sequencing Kits/ Microarray Kits/Informatics Products/ Clinical Research Products/In Vitro Diagnostic/ Products/Molecular Biology Reagents/ Accessory Products

Illumina 測序試劑盒 PE-121-1003

1999年，Illumina只是一家擁有25人的初創公司，主要銷售微陣列芯片(microarray chip)，這種芯片可用來檢測基因組上特定部位的重要變化。

2007年，Illumina宣布以6億美元收購基因測序公司Solexa，從而進軍基因測序市場。Solexa的基因測試技術較競爭對手快百倍，且價格低廉。

2013年收購了無創產前診斷公司Verinata Health。自2005年以來，Illumina在并購領域的投資已超過12億美元。

2014年1月，Illumina發布了新款基因測序儀，可以準確測出全基因組序列，而成本還不到1000美元

上海易匯生物科技有限公司于17年正式銷售Illumina公司基因芯片、二代測序NGS測序儀及相關測序試劑盒等產品

咨詢illumina MiSeq測序試劑盒等產品歡迎您致電 上海易匯生物科技有限公司：1850 1609 238張經理

Illumina公司，致力于新一代測序和芯片技術的生產與開發，提供的產品與應用資訊。Illumina公司創立于1998年4月，是遺傳變異和生物學功能分析領域的優秀的產品、技術和服務供應商。通過幫助客戶加快實現生物信息的采集、分析和應用，來改善人類健康。

As a startup, Illumina aspired to transform human health. Our initial products enabled researchers to explore DNA at an entirely new scale, helping them create the first map of gene variations associated with health, disease, and drug response. Every breakthrough opened up a new world, and showed us how much further there is to go

While the rate of progress is accelerating exponentially, we are only beginning to understand the clinical significance of the genome. What causes a cancer cell to mutate? What is the origin of a puzzling disease? Is it possible to prevent the next outbreak? Or safeguard the world’s food supply? These are just a few of the challenges that inspire us to push the boundaries of our imagination

Today we are a global leader in genomics – an industry at the intersection of biology and technology. At the most fundamental level, we enable our customers to read and understand genetic variations. We strive to make our solutions increasingly simple, more accessible, and always reliable. As a result, discoveries that were unimaginable even a few years ago are now becoming routine – and are making their way into patient treatment.

We now have the ability to sequence at an unprecedented scale. Collectively, this will give us a much deeper understanding of genetics than ever before. We will begin to truly unlock the power of the genome. These advances will trigger a fundamental shift in healthcare and beyond. Medicine will continue to become more preventive and more precise. We will be healthier, longer. We have only just begun.

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics